Spots Global Cancer Trial Database for recurrent endometrial serous adenocarcinoma

Every month we try and update this database with for recurrent endometrial serous adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	NCT05231122	Ovarian Clear C... Platinum-Sensit... Recurrent Endom... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Anti-CD40 Agoni... Bevacizumab Pembrolizumab Quality-of-Life... Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma	NCT05870761	Recurrent Endom...	Biospecimen Col... Computed Tomogr... Dostarlimab Magnetic Resona... Niraparib	18 Years -	Ohio State University Comprehensive Cancer Center
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	NCT05231122	Ovarian Clear C... Platinum-Sensit... Recurrent Endom... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Anti-CD40 Agoni... Bevacizumab Pembrolizumab Quality-of-Life... Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer	NCT03914612	Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Ser... Endometrial Und... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Stage III Uteri... Stage IV Uterin...	Carboplatin Computed Tomogr... Paclitaxel Pembrolizumab Placebo Adminis... Quality-of-Life... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma	NCT05870761	Recurrent Endom...	Biospecimen Col... Computed Tomogr... Dostarlimab Magnetic Resona... Niraparib	18 Years -	Ohio State University Comprehensive Cancer Center
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	NCT05231122	Ovarian Clear C... Platinum-Sensit... Recurrent Endom... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Anti-CD40 Agoni... Bevacizumab Pembrolizumab Quality-of-Life... Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer	NCT00492778	Endometrial End... Endometrial Muc... Endometrial Squ... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Uteri...	3-Dimensional C... Cisplatin Intensity-Modul... Internal Radiat...	-	GOG Foundation

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: